Home › HIV

HIV clinical trials recruiting in the U.S.

131 studies for HIV are recruiting participants at sites across the United States.

HIV (human immunodeficiency virus) attacks the body’s immune system. There is no cure but it can be treated with medicines. To know if you have HIV, get tested.

Cities with the most studies

• Washington, DC21 studies
• New York City, NY18 studies
• Baltimore, MD16 studies
• Houston, TX16 studies
• Miami, FL15 studies
• San Francisco, CA14 studies
• Chicago, IL14 studies
• Atlanta, GA13 studies
• Boston, MA11 studies
• Philadelphia, PA10 studies
• San Diego, CA9 studies
• Seattle, WA8 studies
• Birmingham, AL7 studies
• Los Angeles, CA7 studies
• Dallas, TX6 studies
• Durham, NC6 studies
• New Orleans, LA6 studies
• New Haven, CT6 studies
• Columbus, OH6 studies
• Orlando, FL6 studies
• Tampa, FL5 studies
• The Bronx, NY5 studies
• West Palm Beach, FL5 studies
• Aurora, CO5 studies
• Las Vegas, NV4 studies
• Salt Lake City, UT4 studies
• Nashville, TN4 studies
• St. Louis, MO4 studies
• Cincinnati, OH4 studies
• Newark, NJ4 studies
• Kansas City, MO4 studies
• Port Saint Lucie, FL4 studies
• Austin, TX3 studies
• Memphis, TN3 studies
• Minneapolis, MN3 studies
• Greensboro, NC3 studies
• Burbank, CA3 studies
• Miami Gardens, FL3 studies
• Jacksonville, FL3 studies
• Winston-Salem, NC3 studies

By state

• Alabama9 studies
• California31 studies
• Colorado7 studies
• Connecticut7 studies
• District of Columbia8 studies
• Florida24 studies
• Georgia13 studies
• Illinois14 studies
• Louisiana7 studies
• Maryland29 studies
• Massachusetts11 studies
• Michigan3 studies
• Minnesota3 studies
• Missouri7 studies
• Nevada4 studies
• New Jersey5 studies
• New York21 studies
• North Carolina11 studies
• Ohio9 studies
• Pennsylvania10 studies
• Tennessee7 studies
• Texas22 studies
• Utah4 studies
• Virginia3 studies
• Washington8 studies

Recently updated studies

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.